MGI PHARMA and SuperGen Announce Signing of a Worldwide License Agreement for Dacogen™
MGI PHARMA and SuperGen Announce Signing of a Worldwide License Agreement for Dacogen™
This author has not written his bio yet.
But we are proud to say that webadmin contributed 636 entries already.
MGI PHARMA and SuperGen Announce Signing of a Worldwide License Agreement for Dacogen™
SuperGen Reports Second Quarter Financial Results
SuperGen Announces Publication of Phase II Studies of Dacogen™ in Advanced MDS Patients
SuperGen Submits Application for EMEA Approval of Orathecin™
SuperGen Reports Results of Ongoing Studies of Nipent® in Combination Therapies for Chronic Lymphocytic Leukemia and Low Grade B-cell Lymphomas
SuperGen Reports Promising Results from Phase I Study of Dacogen™ and Carboplatin for Treatment of Advanced Solid Tumors
SuperGen Submits CMC to FDA as First Component of Rolling New Drug Application for Dacogen™
SuperGen Provides Additional Analysis of Response Data from Phase III Study of Dacogen in MDS
SuperGen Announces Study of Novel Regimen Using Nipent® for Hematopoietic Stem Cell Transplantation Published in Journal of Bone Marrow Transplantation
SuperGen Reports 2004 First Quarter Financial Results